-
Thematic Analysis
Global M&A Deals in H1 2026 - Top Themes by Sector: Strategic Intelligence
If you want to understand the themes that drive an industry, simply look at the list of recent mergers and acquisitions (M&As). This report analyzes the disruptive themes that have driven M&A activity in H1 2026 across all sectors including materials, consumer, energy, financials, healthcare, industrials, technology, media & telecoms. The global M&A market in H1 2026 witnessed deals worth $1.7 trillion, a growth of 47% compared to H1 2025. Â The TMT sector led the M&A deal activity, with deals...
-
Q2 2026 CRO Activity and Intel Report
This report offers an in-depth analysis of the contract research organization (CRO) industry, categorized by geography, therapeutic area, and phase of development for Q2 2026.
-
Sector Analysis
Diabetic Macular Edema in Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2035
This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the diabetic macular edema market through 2033. Drug sales in the DME pharmacotherapy market are expected to grow by a significant margin between 2024 and 2034, with an overall compound annual growth rate (CAGR) of 3.4% over the forecast period. In 2024, GlobalData estimated the total DME market to be valued at $4.42 billion across the 7MM, with the US accounting...
-
Sector Analysis
Type 2 Diabetes (T2D): Epidemiology Forecast to 2035
Type 2 diabetes (T2D), formerly known as non-insulin dependent or adult-onset diabetes, is a chronic condition characterized by a non-autoimmune progressive loss of pancreatic beta cells, which produce insulin (Lu et al., 2024; World Health Organization [WHO], 2024). T2D accounts for over 90% of all diabetes cases, with type 1 and gestational diabetes making up the majority of the remaining cases (Goyal, Singhal and Jialal, 2023). T2D most commonly occurs in persons older than 45 years, however its prevalence in...
-
Thematic Analysis
Pharma M&A Deals H1 2026 - Top Themes: Strategic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in H1 2026 in the pharma Sector.
-
Sector Analysis
Epilepsy (Adults) in Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2035
This report covers the 7 major markets and provides an Excel-based forecast model for the epilepsy market through 2035. GlobalData anticipates that the global adult epilepsy market will grow steadily during the forecast period, with 7MM sales expected to increase from $11.4 billion in 2025 to $17.8 billion in 2035, at a compound annual growth rate (CAGR) of 4.5%. In 2025, the US contributed approximately $9.2 billion in drug sales, representing 80.4% of the total adult epilepsy market across the...
-
Sector Analysis
Melanoma: Epidemiology Forecast to 2035
Melanoma is a malignant neoplasm of melanocytes, the pigment cells in the skin located on the epidermis, which is the most superficial layer of the skin (World Health Organization, 2017). Melanoma typically presents as a mole (nevus) on the skin, and is characterized by the growth’s asymmetry, irregular border, color variation, diameter greater than six millimeters, and evolution in appearance over a few weeks or months (Gadeliya Goodson and Grossman, 2009; Goodman and Snyder, 2012). This report focuses on melanoma...
-
Sector Analysis
Bio/Pharmaceutical Outsourcing Report, June 2026
The Bio/Pharmaceutical Outsourcing Report is a monthly analysis of news and trends affecting pharmaceutical Contract Manufacturing Organizations (CMOs). It includes in-depth analyses of the latest business conditions, lists new outsourcing contracts, assesses the latest opportunities and threats for manufacturers, and identifies recent mergers, acquisitions, and financing among CMOs. It also updates readers on facility-level news, such as planned site openings and closures, Good Manufacturing Practice (GMP) inspections, and investments in technology and equipment.
-
Track & Monitor
Merger and Acquisition Trends in Pharma - Q2 2026
This report analyzes the merger and acquisition (M&A) activity in Q2 2026 in the Pharma sector.
-
Track & Monitor
Venture Capital Investment Trends in Pharma - Q2 2026
This report analyzes the venture capital (VC) investment activity in Q2 2026 in the Pharma sector.
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.